PROGNOSTIC IMPACT OF POD24 ACROSS DIFFERENT TREATMENT SETTINGS IN WALDENSTRÖM MACROGLOBULINEMIA TREATED WITH BENDAMUSTINE- RITUXIMAB, DEXAMETHASONE-RITUXIMAB-CYCLOPHOSPHAMIDE AND BTK INHIBITORS (SIE 2026) - Oct 6, 2026 - Abstract #SP059; "Progression of disease within 24 months (POD24) is a vali- dated dynamic prognostic marker in indolent lymphomas, but its role in Waldenström Macroglobulinemia (WM) re- mains incompletely defined across treatment settings and in relation to baseline risk factors and molecular features.Our aim was to evaluate the prognostic impact of POD24 in WM and to compare its discriminatory value with IPSSWM and mutational status.We conducted a multicenter retrospective FIL study including WM patients treated with frontline ben- damustine-rituximab (BR, n=244), frontline dexametha- sone-rituximab-cyclophosphamide (DRC, n=116), and BTK in- hibitors (BTKi) in relapsed disease (n=102: 71 ibrutinib, 31 zanubrutinib). POD24 appeared to provide stronger prognostic dis- crimination than IPSSWM in BR-treated patients, whereas IPSSWM retained greater prognostic value in the DRC co- hort.In conclusion, POD24 is a robust and clinically meaning- ful prognostic marker in WM,..."
Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Lymphoplasmacytic Lymphoma • Waldenstrom Macroglobulinemia • CXCR4 • MYD88
|
|
F. Autore1; Am. Frustaci2; G. Benevolo3; N. Danesin4; D. Giannarelli1; R. Rizzi5; M. Nicolosi6; E. Cencini7; R. Pasquale8; C. Conticello9; S. Steffanoni10; M. Bullo11; D. Marino12; M. Gentile13; I. Innocenti1; L. Stirparo1; F. Piazza4; G. D'Uva3; A. Tedeschi2; L. Laurenti1
|